Advanced Biomed Inc. Financials
This page shows Advanced Biomed Inc. (ADVB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Advanced Biomed’s reported profile is dominated by external financing funding operating cash use, not internally generated cash.
In FY2025, operating cash flow of-$5.8M was nearly matched by free cash flow of-$5.9M , showing that cash consumption was primarily operational rather than driven by capital investment. That deficit was accompanied by$5.9M of financing inflows, but year-end cash remained only$2.9M , indicating proceeds largely offset consumption rather than building a substantial liquidity cushion.
The funding burden intensified: operating cash flow moved from
Leverage rose from 1.7x debt-to-equity to 2.9x, even as the current ratio improved from 1.1x to 1.3x. Total liabilities also expanded from
Financial Health Signals
Advanced Biomed Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Advanced Biomed Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Advanced Biomed Inc. reported a net loss of $3.3M while operations used $5.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Advanced Biomed Inc. reported -$3.3M in net income in fiscal year 2025. This represents a decrease of 17.1% from the prior year.
Advanced Biomed Inc. earned -$0.16 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 14.3% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Advanced Biomed Inc. recorded an outflow of $5.9M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 166.2% from the prior year.
Advanced Biomed Inc. held $2.9M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Advanced Biomed Inc.'s ROE was -93.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 73.6 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Advanced Biomed Inc. invested $910K in research and development in fiscal year 2025. This represents an increase of 3.4% from the prior year.
Advanced Biomed Inc. invested $32K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 57.3% from the prior year.
Not reported for fiscal year 2025.
ADVB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $243K+30.5% | $186K-21.0% | $236K | N/A | $220K+3.6% | $212K+16.9% | $182K | N/A |
| SG&A Expenses | $277K+31.5% | $210K-27.0% | $288K | N/A | $348K+413.6% | $68K-80.0% | $338K | N/A |
| Net Income | -$489K-107.1% | $6.9M+1872.5% | -$387K | N/A | -$1.4M-52.4% | -$908K-241.9% | -$266K | N/A |
| EPS (Diluted) | -$0.38 | $0.31+1650.0% | -$0.02+33.3% | -$0.03+97.8% | -$1.35 | -$0.05 | -$0.01 | -$0.04 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Operating Income, Interest Expense, Income Tax.
ADVB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $10.6M-1.9% | $10.9M+73.8% | $6.2M-54.5% | $13.7M+65.5% | $8.3M+84.0% | $4.5M | N/A | $4.5M |
| Current Assets | $10.5M-1.9% | $10.7M+83.6% | $5.8M-55.9% | $13.2M+71.2% | $7.7M+146.3% | $3.1M | N/A | $3.1M |
| Cash & Equivalents | $2.6M-0.1% | $2.6M-2.0% | $2.7M-7.3% | $2.9M-9.7% | $3.2M+20.0% | $2.6M0.0% | $2.6M+1.5% | $2.6M |
| Total Liabilities | $1.4M+4.9% | $1.4M-57.7% | $3.2M-68.4% | $10.2M+146.3% | $4.2M+7.0% | $3.9M | N/A | $2.8M |
| Current Liabilities | $1.4M+13.7% | $1.3M-58.8% | $3.0M-69.8% | $10.1M+145.4% | $4.1M+7.4% | $3.8M | N/A | $2.7M |
| Total Equity | $9.2M-2.9% | $9.5M+215.6% | $3.0M-13.6% | $3.5M-15.8% | $4.1M+567.1% | $619K-43.4% | $1.1M-34.2% | $1.7M |
| Retained Earnings | -$13.3M-3.8% | -$12.8M+35.0% | -$19.6M-2.0% | -$19.2M-3.8% | -$18.5M-8.1% | -$17.1M | N/A | -$16.0M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
ADVB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$240K+53.3% | -$514K+15.9% | -$610K+60.5% | -$1.5M+54.7% | -$3.4M-305.0% | -$842K-2736.4% | -$30K+93.8% | -$476K |
| Capital Expenditures | $1K-90.2% | $13K+628.7% | $2K-91.2% | $20K+809.7% | $2K-79.3% | -$11K-46.5% | $20K-62.5% | $53K |
| Free Cash Flow | -$241K+54.2% | -$526K+14.0% | -$612K+60.9% | -$1.6M+54.2% | -$3.4M-300.2% | -$853K-1616.8% | -$50K+90.6% | -$529K |
| Investing Cash Flow | -$1K+90.2% | -$13K-628.7% | -$2K+91.2% | -$20K-809.7% | -$2K-120.7% | $11K+153.5% | -$20K+62.5% | -$53K |
| Financing Cash Flow | $268K-15.0% | $315K-29.5% | $447K+158.5% | -$765K-113.0% | $5.9M+1344.8% | $408K+4.0% | $393K+21.3% | $324K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ADVB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -5.3%-77.6pp | 72.3%+85.2pp | -12.9% | N/A | -33.5%+113.2pp | -146.7%-122.4pp | -24.3% | N/A |
| Return on Assets | -4.6%-67.8pp | 63.2%+69.4pp | -6.2% | N/A | -16.7%+3.5pp | -20.2% | N/A | N/A |
| Current Ratio | 7.38-1.2x | 8.56+6.6x | 1.92+0.6x | 1.31-0.6x | 1.88+1.1x | 0.82 | N/A | 1.12 |
| Debt-to-Equity | 0.160.0x | 0.14-0.9x | 1.08-1.9x | 2.94+1.9x | 1.01-5.3x | 6.28 | N/A | 1.68 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Advanced Biomed Inc. Ranks
Frequently Asked Questions
Is Advanced Biomed Inc. profitable?
No, Advanced Biomed Inc. (ADVB) reported a net income of -$3.3M in fiscal year 2025.
What is Advanced Biomed Inc.'s return on equity (ROE)?
Advanced Biomed Inc. (ADVB) has a return on equity of -93.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Advanced Biomed Inc.'s free cash flow?
Advanced Biomed Inc. (ADVB) recorded an outflow of $5.9M in free cash flow during fiscal year 2025. This represents a -166.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Advanced Biomed Inc.'s operating cash flow?
Advanced Biomed Inc. (ADVB) recorded an outflow of $5.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Advanced Biomed Inc.'s total assets?
Advanced Biomed Inc. (ADVB) had $13.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Advanced Biomed Inc.'s capital expenditures?
Advanced Biomed Inc. (ADVB) invested $32K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Advanced Biomed Inc. spend on research and development?
Advanced Biomed Inc. (ADVB) invested $910K in research and development during fiscal year 2025.
What is Advanced Biomed Inc.'s current ratio?
Advanced Biomed Inc. (ADVB) had a current ratio of 1.31 as of fiscal year 2025, which is considered adequate.
What is Advanced Biomed Inc.'s debt-to-equity ratio?
Advanced Biomed Inc. (ADVB) had a debt-to-equity ratio of 2.94 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Advanced Biomed Inc.'s return on assets (ROA)?
Advanced Biomed Inc. (ADVB) had a return on assets of -23.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Advanced Biomed Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Advanced Biomed Inc. (ADVB) held $2.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $5.8M over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Advanced Biomed Inc.'s Piotroski F-Score?
Advanced Biomed Inc. (ADVB) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Advanced Biomed Inc.'s earnings high quality?
Advanced Biomed Inc. (ADVB) reported a net loss of $3.3M while operations used $5.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.